Phase 3
N=40
Efficacy of EUS-guided Celiac Plexus Blockade in Chronic Pancreatitis
Chronic Pancreatitis
Bottom Line
View on ClinicalTrials.gov: NCT00658736 ↗Enrolled (actual)
40
Serious AEs
0.0%
Results posted
Jun 2017
Primary outcome: Primary: Change in Pain Disability Index — 3; 3 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 3
- Interventions
- Triamcinolone (Drug); Bupivicaine alone (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- The Cleveland Clinic
- Primary completion
- Jan 2011
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in Pain Disability Index |
3; 3 | — |
| SECONDARY Change From Baseline in Quality of Life Score at 1 Month - SF12 Physical Component |
-0.2; 1.7 | — |
Summary
This is a triple-blind, parallel group, randomized controlled trial to assess the benefit of triamcinolone injection as a therapeutic measure for control of chronic pancreatitis pain. The treatment group will undergo EUS-CPB with bupivicaine plus triamcinolone ("therapeutic block"). There control group will undergo EUS-CPB with bupivicaine alone ("diagnostic block").
Eligibility Criteria
Inclusion criteria include:
- Age >18 yrs
- Ability for informed consent
- Chronic pancreatic-type abdominal pain (type B) (11).
Exclusion criteria include:
- Pregnancy
- Malignancy
- Recent acute pancreatitis (within 2 months)
- Elevated INR (>1.5) or low platelet count ( 20.
Data sourced from ClinicalTrials.gov (NCT00658736). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.